

**Drugs and Therapeutics (D & T) Committee
Meeting Results
April 15, 2021**

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
Baqsimi	New Drug Initial Review	Preferred	Preferred
Ubrelvy	New Drug Initial Review	Preferred with Prior Approval	Preferred with Prior Approval
Oriahnn	New Drug Initial Review	Preferred with Prior Approval	Preferred with Prior Approval
Viltepso	New Drug Initial Review	Non-preferred	Non-Preferred
Oxbryta	New Drug Initial Review	Non-preferred	Non-preferred
Valtoco	New Drug Initial Review	Tabled until July meeting	Tabled
Zeposia	New Drug Initial Review	Non-preferred	Non-preferred
Nurtec ODT	New Drug Initial Review	Preferred with Prior Approval	Preferred with Prior Approval
Ajovy	New Drug Appeal	Preferred with Prior Approval	Preferred with Prior Approval

**Antiasthmatic Monoclonal Antibodies
Class Review Results**

Dupixent	Preferred with PA
Nucala	Preferred with PA
Fasenra	Non-preferred
Xolair	Preferred with PA
Cinqair	Non-preferred